RIPE-KG · Version 1.1.0 · Resource

ripekg:work/10.1111%2Fbjh.15573

https://w3id.org/ripe/ripe-kg/work/10.1111%2Fbjh.15573
SubjectPredicateObject
ripekg:work/10.1111%2Fbjh.15573Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia prism:doi 10.1111/bjh.15573
ripekg:work/10.1111%2Fbjh.15573Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia dcterms:title Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
ripekg:work/10.1111%2Fbjh.15573Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia rdf:type node1
ripekg:work/10.1111%2Fbjh.15573Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia rdf:type http://purl.org/spar/fabio/Work
ripekg:work/10.1111%2Fbjh.15573Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia rdf:type rdfs:Resource
ripekg:work/10.1111%2Fbjh.15573Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia rdf:type owl:Thing
ripekg:work/10.1111%2Fbjh.15573Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia rdf:type prov:Entity
ripekg:work/10.1111%2Fbjh.15573Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia rdf:type ripe:WorkWork
ripekg:work/10.1111%2Fbjh.15573Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia owl:sameAs https://semopenalex.org/work/W2891044782
ripekg:work/10.1136%2Fbmj-2025-084314Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial http://purl.org/spar/cito/cites ripekg:work/10.1111%2Fbjh.15573Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia